Purpose To evaluate changes in choroidal thickness adjacent to the area of laser application after photodynamic therapy (PDT) in patients with polypoidal choroidal vasculopathy (PCV) using enhanced depth imaging spectraldomain optical coherence tomography. Methods Masked observers measured the choroidal thickness at the subfovea and superior, inferior and temporal areas adjacent to the area of laser application before, 2 days, 1 week and 1 and 3 months after treatment. Results Thirty-seven patients with PCV treated with PDT with verteporfin were included. The mean subfoveal choroidal thickness decreased significantly (P \ 0.001) from 256 ± 115 lm at baseline to 207 ± 111 lm at 3 months; the mean outside choroidal thickness including the superior, inferior and temporal areas decreased significantly (P \ 0.001) from 240 ± 92 lm at baseline to 209 ± 86 lm at 3 months. Conclusion PDT affected not only the subfoveal choroid, but also the choroid outside the area of laser application in PCV.
Introduction
Photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis, Basel, Switzerland) was originally intended to treat age-related macular degeneration (AMD) [1] [2] [3] [4] [5] including polypoidal choroidal vasculopathy (PCV) [5] [6] [7] [8] [9] [10] [11] [12] [13] . However, several studies in which indocyanine green angiography (ICGA) was used report that PDT for AMD or CSC causes choriocapillaric damage and vascular remodeling in the underlying choroid [14] [15] [16] [17] [18] [19] [20] .
Spectral-domain optical coherence tomography (SD-OCT) noninvasively detects morphologic changes in a variety of macular diseases. Spaide et al. [21] recently reported a new method, enhanced depth imaging SD-OCT (EDI-OCT), to evaluate the choroidal status. We previously reported that PDT for PCV leads not only to the occlusion of polyps, but also the subfoveal choroidal thickness increment at 2 days and decrement at 1 month after PDT [22] . It might indicate the morphological choroidal changes in the irradiation area of PDT. However, the effect of PDT on the choroid outside the area of laser application is not fully understood.
In the current study, we retrospectively evaluated changes in the choroidal thickness outside the area of PDT for PCV using EDI-OCT.
Methods
This study followed the tenets of the Declaration of Helsinki. The institutional review board at Fukushima Medical University School of Medicine approved OCT observation for eyes with macular and retinal disorders, the observational study for AMD at treatment and follow-up, and the retrospective comparative analysis performed in this study.
Indirect ophthalmoscopy, slit-lamp biomicroscopy both with a contact lens and without one, digital fluorescein angiography (FA) and ICGA were performed to diagnose PCV. We used a digital imaging system with an infrared camera and a standard fundus camera (TRC-50 IX/IMAGEnet H1024 system, Topcon, Tokyo, Japan) and a confocal laser scanning system (HRA-2, Heidelberg Engineering, Heidelberg, Germany). The best-corrected visual acuity (BCVA) was measured with a standard Japanese decimal visual acuity chart and converted to the logarithm of the minimum angle of the resolution (log MAR) scale for analysis. All eyes were examined with the Heidelberg Spectralis OCT (Heidelberg Engineering).
The diagnostic criteria for PCV were proposed based on the ICGA findings, which imaged the characteristic aneurysmal lesions. All patients with PCV had choroidal neovascularization (CNV) on FA, which was identified as PCV on ICGA. Areas of choroidal vascular hyperpermeability in PCV also were evaluated based on the hyperfluorescence during the middle phase of ICGA. Patients were treated with the standard dose of PDT (6 mg/m 2 ) according to the protocol of the Treatment of AMD with PDT studies [1, 2] , except for the greatest linear dimension (GLD). The GLD was measured on ICGA including thev branching vascular network and polyps [23] [24] [25] . The diameter of the PDT treatment spot size was the GLD plus 1 mm. We applied PDT monotherapy between January 2009 and June 2009 and combination therapy of intravitreal ranibizumab (Lucentis, Genentech, South San Francisco, CA, USA) and PDT between July 2009 and July 2010. Ranibizumab became available for medical use in Japan in March 2009. The patients assigned to combination therapy were treated 1 or 2 days before PDT with intravitreal ranibizumab (0.5 mg/0.05 ml) injected 3.5-4.0 mm posterior to the corneal limbus into the vitreous cavity using a 30-gauge needle after topical anesthesia had been applied. Consecutive monthly intravitreal ranibizumab injections were administered for 3 months.
We observed the choroid and measured the choroidal thickness (defined as the area between the outer RPE surface and the inner scleral surface) using EDI-OCT [21] , in which the Heidelberg Spectralis OCT device is positioned close to the eye to obtain an inverted image. Each section was obtained using eye tracking, and 100 scans were averaged to improve the signal-to-noise ratio. We measured the choroidal thicknesses at the subfovea and 1 mm superior, inferior and temporal to the area of laser application on the horizontal and vertical OCT lines passing through the center of the fovea (Fig. 1) . In most cases, the horizontal and vertical OCT lines shifted from the center of the PDT laser spot. We defined the mean thickness of the choroid outside the area of laser treatment by averaging the thicknesses of the superior, inferior and temporal points.
As we described previously [22] , the choroidal thickness was measured using EDI-OCT before PDT (baseline) and after PDT on day 2, week 1 and months 1 and 3. OCT was performed at all visits. The central retinal thickness including the retinal detachment was also measured at the same time. The patients who received their first PDT treatment remained in the hospital for 2 days to avoid exposure to sunlight. Three months after PDT, the choriocapillaric damage was evaluated on early and middlephase ICGA images.
The measurements obtained from the OCT images represented the average of all the measurements performed by three of the coauthors (YS, IM, AO), who were masked to the treatment status. The VAs are expressed as decimal equivalents and log MAR equivalents. The BCVA and the choroidal and retinal thicknesses were analyzed using the Wilcoxon signed-rank test (SPSS, version 17.0, SPSS Inc., Chicago, IL, USA). P = 0.05 or less was considered significant.
Results
Thirty-seven eyes of 37 patients with PCV (27 men, 10 women; mean age, 72.3 years) were included. Sixteen eyes of 16 patients (12 men, 4 women; mean age, 71.8 years) were treated with PDT monotherapy, and 21 eyes of 21 patients (15 men, 6 women; mean age, 72.8 years) were treated with combination therapy of intravitreal ranibizumab and PDT. The PDT lesion area included the fovea in all cases. The mean spot size for PDT was 3,941 ± 1,145 lm. The OCT measurement range was 30°i n each horizontal and vertical scan, and it was enough to measure choroidal thicknesses of three points outside the laser area in all cases. ICGA on the middle phase showed choroidal vascular hyperpermeability in 27 eyes. The polypoidal lesions disappeared or decreased on ICGA at 3 months in all cases. Three months after PDT, early phase ICGA images showed hypoperfusion represented as choriocapillaric damage in 21 (60 %, 9 with monotherapy and 12 with combination therapy) patients out of 35 patients with 3-month follow-up ICGA.
The mean BCVA level at baseline was 0.39 (0.41 log MAR) and at 3 months, 0.58 (0.24 log MAR), which was significant (P \ 0.001). The data before and after treatment are summarized in Tables 1, 2 and 3. Figures 2 and  3 show a representative case. Figure 4 shows the percent changes in the mean subfoveal choroidal thickness and the choroidal thicknesses outside the area of PDT treatment.
Subfoveal choroidal thickness
The mean subfoveal choroidal thickness increased from 256 ± 115 lm at baseline to 327 ± 101 lm 2 days after PDT (P \ 0.001) and decreased to 254 ± 104 lm by 1 week compared with baseline (P = 0.74), 221 ± 113 lm PDT photodynamic therapy, PCV polypoidal choroidal vasculopathy, M male, F female, BCVA best-corrected visual acuity, logMAR logarithm of the minimal angle of resolution, Day 2 2 days after PDT, 1 week 1 week after PDT, 1 month 1 month after PDT, 3 months 3 months after PDT, CRT central retinal thickness, SCT subfoveal choroidal thickness, Outside average of choroidal thicknesses at superior, inferior and temporal points PDT photodynamic therapy, combination therapy combination therapy of intravitreal ranibizumab and PDT, M male, F female, BCVA bestcorrected visual acuity, logMAR logarithm of the minimal angle of resolution, Day 2 2 days after PDT, 1 week 1 week after PDT, 1 month 1 month after PDT, 3 months 3 months after PDT, CRT central retinal thickness, SCT subfoveal choroidal thickness, Outside average of choroidal thicknesses at superior, inferior and temporal points, SD standard deviation by 1 month compared with baseline (P \ 0.001) and 207 ± 111 lm by 3 months compared with baseline (P \ 0.001).
The choroid was thicker in 27 eyes with choroidal vascular hyperpermeability than in 9 eyes without hyperpermeability on middle-phase baseline ICGA images (mean 291 ± 108 lm vs. 154 ± 74 lm at baseline, P \ 0.001, MannWhitney U test). One eye was not examined by ICGA because the patient was allergic to the dye. PDT photodynamic therapy, monotherapy PDT without using ranibizumab, M male, F female, BCVA best-corrected visual acuity, logMAR logarithm of the minimal angle of resolution, Day 2 2 days after PDT, 1 week 1 week after PDT, 1 month 1 month after PDT, 3 months 3 months after PDT, CRT central retinal thickness, SCT subfoveal choroidal thickness, Outside average of choroidal thicknesses at superior, inferior and temporal points, SD standard deviation Twenty-one eyes with PCV had hypoperfusion in the areas irradiated by PDT seen on ICGA 3 months after treatment (192 ± 92 lm with hypoperfusion vs. 240 ± 137 lm without hypoperfusion, P = 0.26). There was no significant difference between the decrement of choroidal thicknesses with and without hypoperfusion in the area of PDT irradiation 3 months after treatment (mean 51 ± 32 vs. 46 ± 22 lm, P = 0.59).
Choroidal thickness outside the treatment area
The mean choroidal thickness outside the area of laser treatment significantly increased (P \ 0.001) from 240 ± 92 lm at baseline to 295 ± 90 lm 2 days after application of PDT and then continually to 240 ± 87 lm by 1 week (P = 0.82), 220 ± 87 lm by 1 month compared with baseline (P \ 0.001) and 209 ± 86 lm by 3 months compared with baseline (P \ 0.001). The mean choroidal thickness outside the area of laser treatment in 27 eyes with choroidal vascular hyperpermeability in middlephase ICGA images at baseline was thicker than in 9 eyes without hyperpermeability (263 ± 86 vs. 177 ± 64 lm at baseline, P \ 0.01, Mann-Whitney U test). One eye was not examined by ICGA because the patient was allergic to the dye.
There was no significant difference between the decrement in choroidal thicknesses both with and without Fig. 3 Horizontal and vertical enhanced-depth imaging spectral-domain optical coherence tomography images show the choroidal thickness changes in the same case as in Fig. 2 . The choroidal thickness was measured at baseline (a, Fig. 4 The percent changes in the subfoveal choroidal thickness and mean choroidal thickness outside the area of laser treatment after photodynamic therapy to treat polypoidal choroidal vasculopathy (PCV). The mean subfoveal choroidal thickness increased to 128 % on day 2 and decreased to 81 % at 3 months after treatment compared with baseline. The mean choroidal thickness outside the area of laser treatment increased to 123 % on day 2 and decreased to 87 % at 3 months after treatment compared to baseline. Mean outside choroidal thickness = average choroidal thicknesses of the superior, inferior and temporal points hypoperfusion in the area of PDT irradiation 3 months after treatment (mean 33 ± 21 vs. 31 ± 14 lm, P = 0.75).
Photodynamic monotherapy and combination therapy: The treatment data for PCV are summarized in Tables 2  and 3 . The changes in the subfoveal choroidal thicknesses and the choroidal thicknesses outside the area of laser treatment were similar with PDT monotherapy and combination therapy. Although the changes of the mean central retinal thickness also showed a similar trend toward decreased thickness over 3 months, the mean central retinal thickness at 3 months in the cases treated with combination therapy was significantly thinner than in the cases treated with monotherapy (195 ± 74 lm in combination therapy, 275 ± 133 lm in monotherapy, respectively, P \ 0.01, Mann-Whitney U test).
Discussion
PDT for PCV reduced both the subfoveal choroidal thickness and the choroidal thickness outside the area of laser irradiation. PDT seems to affect the choroidal tissue even in the area not directly exposed to treatment.
PDT was originally intended to treat CNV secondary to AMD. We report [26] that PCV is almost half in Japanese patients with neovascular AMD. Because anti-VEGF therapy for PCV may not be sufficient compared to typical AMD [27] [28] [29] , PDT for PCV is still an important option. On the other hand, Sasahara et al. [30] report that ICGA in eyes with PCV sometimes have choroidal vascular hyperpermeability. The effect of PDT for PCV was reported to lead not only to the regression of the polypoidal lesion, but also to the inhibition of choroidal vascular hyperpermeability after treatment [22] . Thus, it is important to evaluate the choroid in eyes with PCV.
ICGA can evaluate choroidal vascular abnormalities, such as choroidal vascular hyperpermeability in PCV. However, in the past there was no method to visualize the choroid noninvasively. Spaide et al. [21] recently reported that EDI-OCT can be used to evaluate morphologic changes in the choroid and measure the choroidal thickness in various diseases. Using EDI-OCT, Margolis et al. [31] report a subfoveal choroidal thickness of 287 lm in normal subjects. Other results [32, 33] also report about 250 lm in normal eyes. On the other hand, several reports mention [34] [35] [36] a choroidal thickening in eyes with PCV compared with eyes either healthy or with typical AMD. In the current study, the choroid was especially thicker in eyes with hyperpermeability compared to those without hyperpermeability. These findings may indicate that the choroidal abnormalities in PCV can be evaluated by measuring the choroidal thickness using EDI-OCT. In the current study, we evaluated the choroidal changes after PDT for PCV using EDI-OCT and observed the reduction of not only the subfoveal choroidal thickness, but also the choroidal thickness outside the area of laser treatment in vivo. Thus, these results in the current study might indicate the PDT for PCV could inhibit the widespread choroidal exudation including the laser irradiation area.
Temporal damage to the choriocapillaries after PDT represented as the hypoperfusion area in ICGA has been reported [14] [15] [16] [17] [18] [19] [20] . In the current cases, however, there was no difference in the choroidal thickness 3 months after PDT in eyes either with or without hypoperfusion. These results may indicate that the influence of choriocapillaric damage is limited in the choroidal thickness in the current study.
The effectiveness of combination therapy with ranibizumab and PDT is expected to manifest not only in the synergetic effects of both treatments, but also through the inhibition of aforementioned side effects. However, there was no significant difference in the choroidal thickness after treatment with PDT for PCV either with or without ranibizumab, which may indicate that the additional effects of ranibizumab in the current study were limited to the choroidal thickness. These results were almost same as those we previously described [22] .
In conclusion, PDT reduced the subfoveal choroidal thickness and the choroidal thickness outside the area of laser treatment in eyes with PCV. PDT might affect the choroidal tissue even in the area not directly exposed to the laser treatment.
The current retrospective study had several weaknesses in that it had a short-term follow-up period and measurement of only three points outside the area of laser application. However, we believe this is the first case series report of PCV relating to influences in choroidal thickness outside the area of PDT. The current findings may suggest the evaluation of choroidal status before and after treatment to understand the effect of PDT for PCV.
